Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Stenotrophomonas Maltophilia Workup

  • Author: Burke A Cunha, MD; Chief Editor: Michael Stuart Bronze, MD  more...
 
Updated: Mar 18, 2016
 

Laboratory Studies

Culture of the organism from body fluids and proper identification from the microbiology laboratory confirms the presence of S maltophilia. Usually, the presence of S maltophilia represents colonization. A potential pathogenic role must be evaluated by an infectious disease specialist. The mere recovery of a potential pathogen from any body fluid does not indicate a pathogenic role for the organism.

Next

Histologic Findings

The histology of S maltophilia in the rare situations when it causes infection is indistinguishable from the histology of infections caused by other aerobic gram-negative bacilli.

Previous
 
 
Contributor Information and Disclosures
Author

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, Oklahoma State Medical Association, Southern Society for Clinical Investigation, Association of Professors of Medicine, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Charles S Levy, MD Associate Professor, Department of Medicine, Section of Infectious Disease, George Washington University School of Medicine

Charles S Levy, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, Medical Society of the District of Columbia

Disclosure: Nothing to disclose.

References
  1. Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis. 2010 May. 29(5):605-8. [Medline].

  2. Burdge DR, Noble MA, Campbell ME, et al. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis. 1995 Feb. 20(2):445-8. [Medline].

  3. Denton M. Stenotrophomonas maltophilia: An emerging problem in cystic fibrosis patients. Rev Med Microbiol. 1997. 8:15-9.

  4. Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant. 2007 Aug. 26(8):834-8. [Medline].

  5. Paschoal IA, de Oliveira Villalba W, Bertuzzo CS, et al. Cystic fibrosis in adults. Lung. 2007 Mar-Apr. 185(2):81-7. [Medline].

  6. Colin AA, Rabin HR. Stenotrophomonas maltophilia in cystic fibrosis: guilty or innocent?. Am J Respir Crit Care Med. 2011 Mar 1. 183(5):564-6. [Medline].

  7. Gopalakrishnan R, Hawley HB, Czachor JS, et al. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: A study of 143 patients. Heart Lung. 1999 Mar-Apr. 28(2):134-41. [Medline].

  8. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010 Jun. 54(6):2735-7. [Medline]. [Full Text].

  9. Gülmez D, Cakar A, Sener B, Karakaya J, Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother. 2010 Oct. 16(5):322-8. [Medline].

  10. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther. 2011 Apr. 9(4):471-88. [Medline].

  11. Alonso A, Martínez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997 May. 41(5):1140-2. [Medline].

  12. Ansari SR, Hanna H, Hachem R, et al. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer. 2007 Jun 15. 109(12):2615-22. [Medline].

  13. Azak A, Kocak G, Huddam B, Iscan G, Duranay M. An unusual cause of continuous ambulatory peritoneal dialysis-associated outpatient peritonitis: Stenotrophomonas maltophilia. Am J Infect Control. 2011 Sep. 39(7):618. [Medline].

  14. Barchitta M, Cipresso R, Giaquinta L, Romeo MA, Denaro C, Pennisi C, et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health. 2009 May. 212(3):330-7. [Medline].

  15. Belvisi V, Fabietti P, Del Borgo C, Marocco R, DI Vincenzo E, Soscia F, et al. Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report. J Chemother. 2009 Jun. 21(3):367-8. [Medline].

  16. Berbari N, Johnson DH, Cunha BA. Xanthomonas maltophilia peritonitis in a patient undergoing peritoneal dialysis. Heart Lung. 1993 May-Jun. 22(3):282-3. [Medline].

  17. Betts JW, Phee LM, Woodford N, Wareham DW. Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2014 Sep. 33(9):1565-72. [Medline].

  18. Blanquer D, De Otero J, Padilla E, Gómez F, Mayol A, Irigaray R, et al. Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother. 2008 Dec. 20(6):761-3. [Medline].

  19. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012 Jan. 25(1):2-41. [Medline]. [Full Text].

  20. Cunha BA. Antibiotic Essentials. 5th ed. Royal Oak, Mich: Physicians Press; 2006.

  21. Cunha BA. Pseudoinfections and pseudo-outbreaks. Mayhall G, ed. Hospital Epidemiology and Infection Control. 2nd ed. Philadelphia, Pa: Lippencott Williams and Wilkins; 1999. 121-30.

  22. Cunha BA. Infections caused by non-fermentative aerobic gram-negative bacilli in the Critical Care Unit. Antibiotics for Clinicians. 2000. 4:11-6.

  23. Cunha BA. Pneumoniae Essentials. 2nd Ed. Royal Oak, MI: Physicians Press; 2008.

  24. Cunha BA, Klein NC. Pseudoinfections: A review. Infect Dis Clin Pract. 1995. 4:95-103.

  25. De Mauri A, Torreggiani M, Chiarinotti D, Andreoni S, Molinari G, De Leo M. Stenotrophomonas maltophilia: an emerging pathogen in dialysis units. J Med Microbiol. 2014 Nov. 63:1407-1410. [Medline].

  26. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998 Jan. 11(1):57-80. [Medline].

  27. Ece G, Erac B, Limoncu MH, Baysak A, Oz AT, Ceylan KC. Stenotrophomonas maltophilia Pseudo-outbreak at a University Hospital Bronchoscopy Unit in Turkey. West Indian Med J. 2014 Jan. 63(1):59-61. [Medline].

  28. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore). 1990 Sep. 69(5):296-306. [Medline].

  29. Elting LS, Khardori N, Bodey GP, et al. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990 Mar. 11(3):134-8. [Medline].

  30. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents. 2009 Jul. 34(1):8.e1-9. [Medline].

  31. Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur J Clin Microbiol Infect Dis. 2009 Jul. 28(7):719-30. [Medline].

  32. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008 Nov. 62(5):889-94. [Medline].

  33. Fang FC, Madinger NE. Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Curr Clin Top Infect Dis. 1996. 16:52-83. [Medline].

  34. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010 Jun. 54(6):2735-7. [Medline]. [Full Text].

  35. Fujita J, Yamadori I, Xu G, et al. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med. 1996 Jan. 90(1):35-8. [Medline].

  36. Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012 Jun. 81(2):114-8. [Medline].

  37. Garcia-Rodriguez JA, Garcia Sanchez JE, Munoz Bellido JL, et al. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. J Chemother. 1991 Jun. 3(3):143-6. [Medline].

  38. Garcia-Teresa MA, Casado-Flores J, Delgado Dominguez MA, et al. Infectious complications of percutaneous central venous catheterization in pediatric patients: a Spanish multicenter study. Intensive Care Med. 2007 Mar. 33(3):466-76. [Medline].

  39. Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 1996 Dec. 40(12):2859-64. [Medline].

  40. Gilardi GL. Characterization of nonfermentative nonfastidious gram negative bacteria encountered in medical bacteriology. J Appl Bacteriol. 1971 Sep. 34(3):623-44. [Medline].

  41. Gilardi GL. Infrequently encountered Pseudomonas species causing infection in humans. Ann Intern Med. 1972 Aug. 77(2):211-5. [Medline].

  42. Gilardi GL. Pseudomonas maltophilia infections in man. Am J Clin Pathol. 1969 Jan. 51(1):58-61. [Medline].

  43. Hansen CR. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen. Curr Opin Pulm Med. 2012 Nov. 18(6):628-31. [Medline].

  44. Cunha Ba. Infectious Disease in Critical Care Medicine. 2nd Ed. New York, NY: Informa Healthcare; 2007.

  45. Kagen J, Zaoutis TE, McGowan KL, et al. Bloodstream infection caused by Stenotrophomonas maltophilia in children. Pediatr Infect Dis J. 2007 Jun. 26(6):508-12. [Medline].

  46. Khardori N, Elting L, Wong E. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990 Nov-Dec. 12(6):997-1003. [Medline].

  47. Khardori N, Reuben A, Rosenbaum B, et al. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother. 1990 Aug. 34(8):1609-10. [Medline].

  48. Krcmery V, Antal M, Langsadl L, et al. Transferable amikacin resistance in pseudomonas maltophilia and acinetobacter calcoaceticus. Infection. 1985 Mar-Apr. 13(2):89-90. [Medline].

  49. Lakatos B, Jakopp B, Widmer A, Frei R, Pargger H, Elzi L, et al. Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia. Infection. 2014 Jun. 42(3):553-8. [Medline].

  50. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009 May. 9(5):312-23. [Medline].

  51. Matsuyama JR, Beail B, Wallis C, et al. Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials. Clin Pharm. 1991 Jul. 10(7):544-8. [Medline].

  52. Milne KE, Gould IM. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother. 2012 Aug. 56(8):4071-7. [Medline]. [Full Text].

  53. Milne KE, Gould IM. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother. 2012 Aug. 56(8):4071-7. [Medline]. [Full Text].

  54. Morrison AJ Jr, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol. 1986 Jul. 24(1):52-5. [Medline].

  55. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007 Apr. 26(4):229-37. [Medline].

  56. Nseir S, Di Pompeo C, Brisson H, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care. 2006. 10(5):R143. [Medline].

  57. Sattler CA, Mason EO Jr, Kaplan SL. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis. 2000 Dec. 31(6):1321-30. [Medline].

  58. Saugel B, Eschermann K, Hoffmann R, et al. Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients. Eur J Clin Microbiol Infect Dis. 2012 Jul. 31(7):1419-28. [Medline].

  59. Semel JD, Trenholme GM, Harris AA, et al. Pseudomonas maltophilia pseudosepticemia. Am J Med. 1978 Mar. 64(3):403-6. [Medline].

  60. Shigemura K, Arakawa S, Tanaka K, Fujisawa M. Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics. J Infect Chemother. 2009 Feb. 15(1):18-22. [Medline].

  61. Shiratori S, Wakasa K, Okada K, Sugita J, Akizawa K, Shigematsu A, et al. Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience. Clin Transplant. 2014 Jun. 28(6):656-61. [Medline].

  62. Steere AC, Tenney JH, Mackel DC. Pseudomonas species bacteremia caused by contaminated normal human serum albumin. J Infect Dis. 1977 May. 135(5):729-35. [Medline].

  63. Sutter VL. Identification of Pseudomonas species isolated from hospital environment and human sources. Appl Microbiol. 1968 Oct. 16(10):1532-8. [Medline].

  64. Tekce YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother. 2012 Jun. 24(3):150-4. [Medline].

  65. Vidigal PG, Dittmer S, Steinmann E, Buer J, Rath PM, Steinmann J. Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. Int J Med Microbiol. 2014 Jul. 304(5-6):613-9. [Medline].

  66. Villarino ME, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol. 1992 Apr. 13(4):201-6. [Medline].

  67. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013 Jan 4. [Medline].

  68. Wilsher ML, Kolbe J, Morris AJ, et al. Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis. Am J Respir Crit Care Med. 1997 Apr. 155(4):1436-40. [Medline].

  69. Wishart MM, Riley TV. Infection with Pseudomonas maltophilia hospital outbreak due to contaminated disinfectant. Med J Aust. 1976 Nov 6. 2(19):710-2. [Medline].

  70. Wu Y, Shao Z. High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia. Chin Med J (Engl). 2014. 127(17):3199. [Medline].

  71. Yeshurun M, Gafter-Gvili A, Thaler M, et al. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010 Jun. 38(3):211-5. [Medline].

  72. Yu VL, Rumans LW, Wing EJ, et al. Pseudomonas maltophilia causing heroin-associated infective endocarditis. Arch Intern Med. 1978 Nov. 138(11):1667-71. [Medline].

  73. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015. 6:893. [Medline].

  74. Sánchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol. 2015. 6:658. [Medline].

  75. Juhász E, Krizsán G, Lengyel G, Grósz G, Pongrácz J, Kristóf K. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob. 2014 Dec 31. 13:333. [Medline].

  76. Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 2016 Apr. 71 (4):1071-5. [Medline].

  77. De Mauri A, Torreggiani M, Chiarinotti D, Andreoni S, Molinari G, De Leo M. Stenotrophomonas maltophilia: an emerging pathogen in dialysis units. J Med Microbiol. 2014 Nov. 63 (Pt 11):1407-10. [Medline].

  78. Cunha CB, Cunha BA. Antibiotic Essentials. 15th ed. New Delhi: JayPee Medical Publishers; 2016.

  79. Cunha BA. Antibiotic Essentials. 3rd ed. Sudbury, MA: Jones & Bartlett; 2010.

  80. Cunha BA. Infectious Disease in Critical Care Medicine. 3rd ed. New York, NY: Informa Healthcare; 2010.

Previous
Next
 
Table 1. Hospital-Acquired S maltophilia Infections
InfectionPredisposing Factor
Catheter-associated bacteriuriaIndwelling urinary catheters
Intravenous line infectionsCentral intravenous catheters
UrosepsisUrinary tract instrumentation
Primary bacteremiaArterial monitoring devices
PseudobacteremiaContamination of blood during collection/processing of blood cultures
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.